NAMA
BMRN icon

Nikko Asset Management Americas’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nikko Asset Management Americas’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,300
Closed -$121K – 285
2017
Q3 		$121K Hold
1,300
– – 0.01% 277
2017
Q2 		$118K Hold
1,300
– – 0.01% 252
2017
Q1 		$114K Buy
+1,300
New +$116K 0.01% 254

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nikko Asset Management Americas's BMRN Position: Q4 2017 in Review

Nikko Asset Management Americas sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 1,300 shares — an estimated $121K sold.

Nikko Asset Management Americas first reported a position in BMRN in Q1 2017 and held it in 3 quarters. The position peaked at $121K in Q3 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

  • Nikko Asset Management Americas reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Nikko Asset Management Americas sold 1,300 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $121K.
  • Nikko Asset Management Americas first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • Nikko Asset Management Americas's BioMarin Pharmaceuticals position peaked at $121K in Q3 2017.
  • 438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Nikko Asset Management Americas's 13F filing for Q4 2017, filed 14 Feb 2018.